Navigation Links
Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Date:10/23/2007

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

"We are really looking forward to treating patients in this trial," said Principal Investigator Dr. James Spicer. "The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to stan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...Nov. 5 SpineSmith Partners has sig...-develop a unique scaffold that mimics the structu...on of several commercial products by SpineSmith,s ...elieves the GenOsteo scaffold represents a signifi...ue and ideal environment for the delivery of adult...
(Date:11/5/2009)... LASIK Surgery and vision correction experts l... actively involved at the recently concluded Ameri...ting in San Francisco, California. Dr. Stephen Bri...n Davidorf, MD, Dr. Peter Rapoza, MD, Dr. Michael ...Bowman, MD, Dr. Edward Manche, MD, and Dr. Parag M...
(Date:11/4/2009)... The Human Anthrax Vaccine Program must be sto...feature film "A Call to Arms:2009 Edition&quo...atal Immunity: The Human Anthrax Vaccine Story&quo...t danger of top secret government science turned i...untability to its victims. It is available for wo...
(Date:11/4/2009)...ILLE, Md., Nov. 4 Zyngenia, Inc., ...n next-generation antibody drug development, today...es A funding from New Enterprise Associates (NEA),... The capital will be used to create novel, multi-s...r more biological targets with a single agent. The...
Breaking Biology Technology:SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 2Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 3Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 5Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 6Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 7Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4
... PAREXEL International,Corporation (Nasdaq: PRXL ...anization, today announced the successful completi...tional Clinical Research Co., Ltd. ("APEX") in,a s...uisition and other,factors discussed herein, the C...uidance for the first quarter of Fiscal Year 2008 ...
... Sept. 26 InterMune, Inc.,(Nasdaq: ITMN ) today ...025,000 shares of common stock at a price to the p...s of common stock, representing the exercise,by th...nal shares in the,offering. The net proceeds to th...million, after payment of underwriting discounts a...
...., Sept. 26 Corium International,Inc., a privatel...nounced,that it has completed a $25.1 million Seri...res. Quantum Technology Partners, Aphelion Capital... round. In connection with,the financing, StrataGe...Ventures portfolio company focused on needle-free ...
Other Biology Technology:PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 4InterMune Announces Closing of Public Offering of Common Stock 2Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures 2Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures 3Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures 4
(Date:11/6/2009)... Center and the Chinese Academy of Sciences (CAS) ...on Taste and Smell Research. Organized by Monell i...the first international meeting on taste and smell...utive Officer, American Association for the Advanc...e magazine, will open the meeting with a plenary a...
(Date:11/5/2009)...ty have developed synthetic molecules capable of e...-infected cells, as well as to prostate cancer cel...al of the American Chemical Society , could lead t... , The molecules called "antibody-recruiting m...iting molecule targeting prostate cancer" (ARM-P) ...
(Date:11/4/2009)...ant to officially endorse green tea as a cancer pr...its protective effects, including results of a new...a journal of the American Association for Cancer R...cer. , Vassiliki Papadimitrakopoulo, M.D., prof...ad and Neck Medical Oncology at the University of ...
Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2New synthetic molecules trigger immune response to HIV and prostate cancer 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2UNC scientists garner new NIH awards for high risk transformative research 10076 1UNC scientists garner new NIH awards for high risk transformative research 10076 2UNC scientists garner new NIH awards for high risk transformative research 10076 3UNC scientists garner new NIH awards for high risk transformative research 10076 4Thomson Reuters Predicts Nobel Laureates 14245 1Thomson Reuters Predicts Nobel Laureates 14245 2Thomson Reuters Predicts Nobel Laureates 14245 3Thomson Reuters Predicts Nobel Laureates 14245 4Thomson Reuters Predicts Nobel Laureates 14245 5Thomson Reuters Predicts Nobel Laureates 14245 6RetireSafe to Senate 3A Stop Proposed Rationing of High Quality Hospital Care Medicare Needs More Physician Hospitals 58219 1RetireSafe to Senate 3A Stop Proposed Rationing of High Quality Hospital Care Medicare Needs More Physician Hospitals 58219 2
.... A hypertension medication called olmesartan med...the arteries that occurs in patients with high blo... Ferrario, M.D., one of the study,s lead investiga... Research Center at Wake Forest University Baptist... the growing evidence for the role of angiotensin ...
...he Smithsonian,s National Zoo have performed the f...s horse ( E. ferus przewalskii ; E. caballus prze...-VAL-skeez. Przewalksi,s horses are a horse specie...xtinct in the wild in 1970. Currently, there are a...oological institutions throughout the world and in...
...nce and technology policymaking capacity of the Wh...ent can better address key issues facing the natio...rity, and the ability of the United States to comp...primary recommendations are that: , The next P...ader to be Assistant for Science and Technology Po...
Other Biology News:Hypertension treatment effective in reversing vascular damage 2First successful reverse vasectomy on endangered species performed at the National Zoo 2First successful reverse vasectomy on endangered species performed at the National Zoo 3White House science office needs upgrade 2White House science office needs upgrade 3
Human SLPI ELISA Kit from R&D Systems
Rabbit Anti-Human OLFM1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
GELase 50X Reaction Buffer from EPICENTRE Biotechnologies
Axl, phospho ELISA development Kit, DuoSet IC Economy Pack from R&D Systems
Biology Products: